Declan Doogan - Jun 15, 2020 Form 4/A - Amendment Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role
Director
Signature
/s/ Jim Engelhart, Attorney-in-Fact
Stock symbol
BHVN
Transactions as of
Jun 15, 2020
Transactions value $
-$2,829,152
Form type
4/A - Amendment
Date filed
2/11/2022, 08:41 PM
Date Of Original Report
Jun 17, 2020
Previous filing
Feb 11, 2022
Next filing
Jun 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Sale -$167K -2.46K -0.34% $67.83* 726K Jun 15, 2020 By the Declan Doogan 2014 Trust F1, F2
transaction BHVN Common Shares Sale -$909K -13.3K -3.84% $68.15* 334K Jun 15, 2020 Direct F2, F3
transaction BHVN Common Shares Sale -$1.06M -15.5K -2.24% $68.58* 676K Jun 16, 2020 By the Declan Doogan 2014 Trust F2, F4
transaction BHVN Common Shares Sale -$690K -10K -2.99% $68.97* 324K Jun 16, 2020 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Declan Doogan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 - $67.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2 This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.86 - $68.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 - $68.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.77 - $69.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.